Gupta, S., Rosenberg, J. E., Mckay, R. R., Flaig, T. W., Petrylak, D. P., Hoimes, C. J., … Milowsky, M. I. (2023). Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).

Gupta, Shilpa, Jonathan E. Rosenberg, Rana R. Mckay, Thomas W. Flaig, Daniel P. Petrylak, Christopher J. Hoimes, Terence W. Friedlander, et al. “Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.

Gupta S, Rosenberg JE, Mckay RR, Flaig TW, Petrylak DP, Hoimes CJ, et al. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.

Gupta, Shilpa, et al. “Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.

Gupta S, Rosenberg JE, Mckay RR, Flaig TW, Petrylak DP, Hoimes CJ, Friedlander TW, Bilen MA, Srinivas S, Burgess EF, Merchan JR, Tagawa ST, Brown JR, Yu Y, Carret A-S, Wirtz H, Guseva M, Moreno BH, Milowsky MI. Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin plus pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. JOURNAL OF CLINICAL ONCOLOGY. 2023.